Pharmicell (005690) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Pharmicell KRW 13,794, price KRW 12,540, upside +10.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pharmicell for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 4,275 KRW – 20,250 KRW · fair‑value band 8,152 KRW – 26,473 KRW · the 12,540 KRW price screens below the 13,794 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Pharmicell in your weekly email
Every Wednesday you see whether Pharmicell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions.
Show more
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Stock analysis
Pharmicell (005690) currently trades at 12,540 KRW, while our model-based Fair Value estimate is 13,794 KRW, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 19,896 KRW per share, and 9 of the 26 models we run sit above the 12,540 KRW price.
Bear case: the Asset-Based group reads lowest at 1,383 KRW, and 17 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 8,152 KRW (bear) to 26,473 KRW (bull), the price of 12,540 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Pharmicell reported revenue of 114B KRW in FY2025 versus 51.8B KRW in FY2021, a compound +21.8%/yr. Reported net income was 40.3B KRW in FY2025, compounding +43.7%/yr from FY2021.
Key figures
Market cap 752B KRW (≈ $553M) · P/S ratio 28.0 · Dividend yield 0.4% · Net margin 35.3% · Return on equity −29.3% · Return on assets (EBIT) 8.9% · Operating margin −86.0% · Revenue growth (YoY) −58.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 10%, 005690 screens cheaper than that median.
Fair Value models
Bear 8,152 KRWFair Value 13,794 KRWBull 26,473 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+75.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
’12
’13
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+25.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.5%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 30%
2025 sits 536% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +10.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+10% · Top 25%
Profitability
Return on assets−5% · Above median
Net margin (TTM)−112% · Bottom 25%
Operating margin (TTM)−86% · Bottom 25%
Growth and dividend
Revenue growth−58% · Bottom 25%
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharmicell Fair Value". https://www.fairvalue-calculator.com/stock/005690
Frequently asked questions
Is Pharmicell (005690) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 13,794 KRW versus a price of 12,540 KRW, about +10% upside (undervalued).
What is the fair value of 005690?
Our model-based fair value for Pharmicell is 13,794 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 12,540 KRW.
What is the quality score of 005690?
Pharmicell has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmicell (005690)?
Our model-based price target is the fair value of 13,794 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 8,152 KRW, optimistic scenario 26,473 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmicell stock forecast for 2026?
Our models put fair value at 13,794 KRW, about +10% upside versus a price of 12,540 KRW (undervalued). Cautious scenario 8,152 KRW, optimistic scenario 26,473 KRW. The calculation is refreshed regularly with new filings.
Does Pharmicell pay a dividend?
Pharmicell currently shows a dividend yield of about 0.40% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Pharmicell (005690)?
For today's price to be fair in a discounted-cash-flow model, Pharmicell would have to grow free cash flow by +13.2 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 005690 use?
Our models discount Pharmicell at 10.5 %: a base by market capitalisation (small), damped by beta 0.59, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharmicell that is +13.2 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Pharmicell (005690) delivered so far?
Over the past 5 years revenue at Pharmicell grew +24.8 % a year. The price currently implies +13.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharmicell (005690) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Pharmicell (+13.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharmicell (005690)?
The free-cash-flow yield on the price is 4.46 %: that much free cash flow Pharmicell produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharmicell (005690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmicell it is 13,794 KRW per share (as of Sep 24, 2026), against a price of 12,540 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Pharmicell stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 005690 trades below its calculated fair value: price 12,540 KRW, fair value 13,794 KRW, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 005690?
No. The price is what the market pays today (12,540 KRW); the fair value is what the company's own numbers justify (13,794 KRW). For Pharmicell the two are 1,254 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmicell worth?
The market values Pharmicell at about 752B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 12,540 KRW; our models calculate a fair value of 13,794 KRW per share.
What do the bullish and bearish scenarios say about 005690?
Our models span a range for Pharmicell: cautious scenario 8,152 KRW, base 13,794 KRW, optimistic 26,473 KRW per share (as of Sep 24, 2026, price 12,540 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmicell (005690)?
Balance-sheet figures for Pharmicell (as of Sep 24, 2026): return on equity −29.3%, debt of 0.07 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 005690 from its 52-week high?
Pharmicell trades at 12,540 KRW, about 38% below its 52-week high of 20,250 KRW and 43% above the low of 8,760 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 13,794 KRW is for.
Which stocks are comparable to Pharmicell?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmicell stock attractive at the current price?
The data as of Sep 24, 2026: price 12,540 KRW, calculated fair value 13,794 KRW (+10%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 005690 calculated?
We run Pharmicell through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13,794 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Pharmicell currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmicell (005690)?
The closing price on Sep 23, 2026 was 12,540 KRW. Our model-based fair value is 13,794 KRW, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmicell right now?
The model range is unusually wide (8,152 KRW to 26,473 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Pharmicell
How large is the market capitalisation of Pharmicell (005690)?
The market capitalisation of Pharmicell is 752B KRW (≈ $553M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmicell (005690)?
The price-to-sales ratio of Pharmicell is 28.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Pharmicell (005690)?
The dividend yield of Pharmicell is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharmicell (005690)?
The net margin of Pharmicell is 35.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmicell (005690)?
The return on equity (ROE) of Pharmicell is −29.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmicell (005690)?
On an EBIT basis the return on assets of Pharmicell is 8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmicell (005690)?
The operating margin of Pharmicell is −86.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmicell (005690)?
Revenue at Pharmicell is growing −58.2% versus a year earlier (3y avg +23.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Pharmicell (005690) carry?
The net debt of Pharmicell is 2.3B KRW (fiscal year 2022, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharmicell in the live analysis
One click puts Pharmicell on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
